Talk:Kinin–kallikrein system

Untitled

I've found a nice long in-depth review (PMID 16177542, also free as it happens) that I expect to be using to update this page... provided the wards are quiet tonight. JFW | T@lk 11:10, 8 May 2006 (UTC)

Another historical resource, but I have no access to it at present[1]. JFW | T@lk 20:17, 29 June 2006 (UTC)

Risk of cardiovascular disease

doi:10.1111/j.1538-7836.2007.02687.x JFW | T@lk 20:49, 5 July 2007 (UTC)

Review

Another recent review: doi:10.1111/j.1538-7836.2007.02770.x JFW | T@lk 09:10, 21 September 2007 (UTC)

Arcadian

... removed the following sources on which I initially based the article:

• Dendorfer A, Wolfrum S, Dominiak P. Pharmacology and cardiovascular implications of the kinin-kallikrein system. Jpn J Pharmacol 1999;79:403-26. PMID 10361880.
• Skidgel RA, Alhenc-Gelas F, Campbell WB. Relation of cardiovascular signaling by kinins and products of similar converting enzyme systems; prologue: kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol 2003;284:H1886-91. PMID 12742820.

They might still be useful someday. JFW | T@lk 20:01, 25 November 2010 (UTC)

New review

doi:10.1111/jth.13194 JFW | T@lk 09:29, 15 November 2015 (UTC)

What is ESR?

"Clinical symptoms include marked weakness, tachycardia, fever, leukocytosis and acceleration of ESR." But what is ESR?

DlronW (talk) 07:20, 1 October 2021 (UTC)